1926203-09-9

1926203-09-9 structure

Name: Troriluzole
Chemical Name: BHV-4157
CAS Number: 1926203-09-9
Molecular Formula: C₁₅H₁₆F₃N₅O₄S
Molecular Weight: 419.379
Catalog: Research Areas Neurological Disease
Create Date: 2020-01-11 18:27:18
Modify Date: 2024-01-01 17:19:54
Trigriluzole (BHV-4157) is a novel glutamate modulator for the treatment of mild-to-moderate Alzheimer’s disease (AD); Trigriluzole is a third-generation prodrug and new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. Trigriluzole has a wide range of pharmacological actions, including interactions with several types of ion channels, cellular signaling mechanisms and facilitation of glutamate reuptake. Some potential targets related to trigriluzole’s mechanism of action include (1) reducing presynaptic glutamate release through actions at the voltage-gated ion channels, (2) facilitating glutamate uptake via EAATs located on glial cells, (3) enhancing transmission through synaptic AMPA receptors, (4) altering GABAergic neurotransmission, and (5) effecting neurotrophic agents such as BDNF. Anxiety Phase 3 Clinical

Name	BHV-4157
Synonyms	Glycinamide, glycylglycyl-N2-methyl-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- Glycylglycyl-N2-methyl-N-[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]glycinamide S7H48S6K7H BHV-4157

Description	Trigriluzole (BHV-4157) is a novel glutamate modulator for the treatment of mild-to-moderate Alzheimer’s disease (AD); Trigriluzole is a third-generation prodrug and new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. Trigriluzole has a wide range of pharmacological actions, including interactions with several types of ion channels, cellular signaling mechanisms and facilitation of glutamate reuptake. Some potential targets related to trigriluzole’s mechanism of action include (1) reducing presynaptic glutamate release through actions at the voltage-gated ion channels, (2) facilitating glutamate uptake via EAATs located on glial cells, (3) enhancing transmission through synaptic AMPA receptors, (4) altering GABAergic neurotransmission, and (5) effecting neurotrophic agents such as BDNF. Anxiety Phase 3 Clinical
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Neurological Disease
Target	glutamate[1]
In Vitro	Troriluzole is absorbed systemically and cleaves into riluzole by aminopeptidases[1].
References	[1]. Schanzer B, et al. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019 Nov;28(11):1003-1012. [2]. Huang LK, et al. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020 Jan 6;27(1):18.